Carvykti takes off
Meanwhile, Tecvayli stalls, but J&J still hopes for growth.
T-cell engagers enter new pivotal studies
New listings reveal expanded phase 3 programmes for J&J’s Talvey and Amgen’s tarlatamab.
Meanwhile, Tecvayli stalls, but J&J still hopes for growth.
New listings reveal expanded phase 3 programmes for J&J’s Talvey and Amgen’s tarlatamab.
